TISIDB

Summary
Symbol	NRXN2
Name	neurexin 2
Aliases	neurexin II; Neurexin II-beta; Neurexin-2-beta
Chromosomal Location	11q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Membrane Single-pass type I membrane protein
Domain	PF02210 Laminin G domain PF01034 Syndecan domain
Function	Neuronal cell surface protein that may be involved in cell recognition and cell adhesion.

> Gene Ontology [ TOP ]
Biological Process	GO:0001505 regulation of neurotransmitter levels GO:0001941 postsynaptic membrane organization GO:0006836 neurotransmitter transport GO:0007158 neuron cell-cell adhesion GO:0007269 neurotransmitter secretion GO:0007416 synapse assembly GO:0007611 learning or memory GO:0007612 learning GO:0007638 mechanosensory behavior GO:0009612 response to mechanical stimulus GO:0010996 response to auditory stimulus GO:0023061 signal release GO:0030534 adult behavior GO:0031223 auditory behavior GO:0035176 social behavior GO:0035418 protein localization to synapse GO:0042297 vocal learning GO:0043113 receptor clustering GO:0044091 membrane biogenesis GO:0044708 single-organism behavior GO:0050808 synapse organization GO:0050890 cognition GO:0051668 localization within membrane GO:0051703 intraspecies interaction between organisms GO:0051705 multi-organism behavior GO:0071625 vocalization behavior GO:0071709 membrane assembly GO:0072657 protein localization to membrane GO:0097104 postsynaptic membrane assembly GO:0097106 postsynaptic density organization GO:0097107 postsynaptic density assembly GO:0097116 gephyrin clustering involved in postsynaptic density assembly GO:0097118 neuroligin clustering involved in postsynaptic membrane assembly GO:0097119 postsynaptic density protein 95 clustering GO:0098596 imitative learning GO:0098597 observational learning GO:0098598 learned vocalization behavior or vocal learning GO:0099068 postsynapse assembly GO:0099531 presynaptic process involved in chemical synaptic transmission GO:0099643 signal release from synapse GO:1904861 excitatory synapse assembly
Molecular Function	GO:0005246 calcium channel regulator activity GO:0016247 channel regulator activity GO:0050839 cell adhesion molecule binding GO:0097109 neuroligin family protein binding
Cellular Component	GO:0098793 presynapse

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04514 Cell adhesion molecules (CAMs)
Reactome	R-HSA-6794361: Interactions of neurexins and neuroligins at synapses R-HSA-112316: Neuronal System R-HSA-6794362: Protein-protein interactions at synapses

Summary
Symbol	NRXN2
Name	neurexin 2
Aliases	neurexin II; Neurexin II-beta; Neurexin-2-beta
Chromosomal Location	11q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between NRXN2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	NRXN2
Name	neurexin 2
Aliases	neurexin II; Neurexin II-beta; Neurexin-2-beta
Chromosomal Location	11q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of NRXN2 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	NRXN2
Name	neurexin 2
Aliases	neurexin II; Neurexin II-beta; Neurexin-2-beta
Chromosomal Location	11q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of NRXN2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.889	0.0914
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-1.451	0.153
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.483	0.587
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.12	0.786
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.347	0.84
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.706	0.75
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.762	0.188
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.101	0.914
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	1.745	0.0758
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.155	0.907
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.38	0.83
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.097	0.646

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of NRXN2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	5.9	-5.9	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	7.1	-7.1	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	2.7	4.7	0.294
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	3.4	4	0.587
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	14.3	0	14.3	0.238
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	15.4	0	15.4	0.482
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	0	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	18.4	0	18.4	0.0356
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	18.2	0	18.2	0.274
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	18.8	0	18.8	0.228
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	NRXN2
Name	neurexin 2
Aliases	neurexin II; Neurexin II-beta; Neurexin-2-beta
Chromosomal Location	11q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NRXN2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	NRXN2
Name	neurexin 2
Aliases	neurexin II; Neurexin II-beta; Neurexin-2-beta
Chromosomal Location	11q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NRXN2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NRXN2. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	NRXN2
Name	neurexin 2
Aliases	neurexin II; Neurexin II-beta; Neurexin-2-beta
Chromosomal Location	11q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NRXN2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	NRXN2
Name	neurexin 2
Aliases	neurexin II; Neurexin II-beta; Neurexin-2-beta
Chromosomal Location	11q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of NRXN2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	NRXN2
Name	neurexin 2
Aliases	neurexin II; Neurexin II-beta; Neurexin-2-beta
Chromosomal Location	11q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between NRXN2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	NRXN2
Name	neurexin 2
Aliases	neurexin II; Neurexin II-beta; Neurexin-2-beta
Chromosomal Location	11q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting NRXN2 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse NRXN2